Early Access Program

Home
Products & Services
Early Access Program

Help us change the way your patients receive immunotherapy

elive™ Test is now available to clinicians for research use under the Early Access Program

Select clinicians are now eligible for early access to elive™ Test under Elephas research and development programs. Support our mission to improve the lives of cancer patients by providing valuable data and feedback on your patients’ cancer care.

Early access to elive™ Test reports is provided for research use only (RUO).

Take the next step and contact us.

Pipetting under the BSC (Biological Safety Cabinet)

More about the Early Access Program:

elive™ Test must be ordered by a licensed U.S. healthcare provider.
Available to patients with suspected or confirmed solid tumor, who are candidates for ICI therapy and eligible for core needle biopsy.
Patients and providers willing to provide diagnosis, treatment, and clinical follow-up data to support Elephas’ research and development programs.
Early access RUO testing with elive™ Test is not eligible for reimbursement. Patient and provider will not be billed for the RUO test.
Program participation and availability may be limited.